|
South San Francisco, CA, February 28, 2003 — Telik,
Inc. (Nasdaq: TELK) announced that Michael M. Wick, M.D., Ph.D.,
chairman and chief executive officer, will present a company update
at the 6th Annual Lehman Bothers Global Healthcare Conference on
Tuesday, March 4, 2003 at 3:15 p.m. Eastern time at the Loews Miami
Beach Hotel in Miami Beach, Florida.
Telik, Inc. of South San Francisco, CA is a biopharmaceutical company
working to discover, develop and commercialize small molecule drugs
to treat serious diseases for which there is significant demand
for new therapies. The company’s most advanced drug development
candidates are TLK286, a tumor activated small molecule drug that
is in Phase 2 clinical trials in ovarian, non-small cell lung, colorectal
and breast cancer, and TLK199, a small molecule myelostimulant.
Telik’s product candidates were discovered using its proprietary
drug discovery technology, TRAP, which enables the rapid and efficient
discovery of small molecule drug candidates. Additional information
is available at www.telik.com.
You should not rely on forward-looking statements contained in
this press release. Telik can give no assurance with regard to these
statements, as they are subject to various risks and uncertainties.
All of Telik’s product candidates, including TLK286 and TLK199,
are in the early stages of development, and the potential benefits
of each must still be proven. More detailed information regarding
factors that may cause actual results to differ materially from
the results expressed or implied by statements in this press release
may be found in Telik's periodic filings with the Securities and
Exchange Commission. Telik assumes no obligation to update any information
in this press release.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
